跳至主要内容
临床试验/NCT07699276
NCT07699276招募中2 期

Steroid-sparing Regimen With Olanzapine and Ondansetron to Prevent Emesis Caused by High Dose Cisplatin in Solid Cancer Patient : A Single Arm Phase II Study

Mahidol University1 个研究点 分布在 1 个国家目标入组 95 人开始时间: 2026年2月10日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
招募中
入组人数
95
试验地点
1
主要终点
complete response rate

研究概览

简要总结

A phase II study evaluating dexamethasone sparing regimen with olanzapine and palonosetron for patients receiving high dose cisplatin to prevent chemotherapy induced nausea and vomiting

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • histologically confirmed solid malignancy
  • scheduled for first cycle of cisplatin at dosage of at least 50 mg/m2

排除标准

  • pregnancy
  • pelvic or abdominal radiation within 4 weeks
  • uncontrolled brain metastasis
  • other moderate or high emetic risk chemotherapy on day 2-5
  • untreated gut obstruction
  • known allergy or severe adverse effect from palonosetron or olanzapine
  • AST/ ALT > 2.5x or serum creatinine clearance less than 50 ml/min

研究组 & 干预措施

study arm

Experimental

olanzapine palonosetron with dexamethasone on day 1 only

干预措施: dexamethasone sparing (Drug)

结局指标

主要结局

complete response rate

时间窗: 5 days after receiving chemotherapy

no vomiting and no rescue therapy

次要结局

  • no -nausea rate(5 days after receiving chemotherapy)
  • degree of nausea vomiting(5 days after receiving chemotherapy)
  • adverse effects(5 days after receiving chemotherapy)
  • rescue therapy(5 days after chemotherapy)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验